Treatment With Local PPARgamma Ligand in Distal Ulcerative Colitis

Herlev Hospital

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Ulcerative Colitis

Treatments: Drug: Rosiglitazone

Study type: Interventional

Funder types: Other

Identifiers

NCT00309660

PPAR2005

Details and patient eligibility

About

Treatment with PPARgamma ligands have been shown to reduces intestinal inflammation in murine models of colitis. The aim of this study was to evaluate the effect of treatment with local PPARgamma ligand (rosiglitazone) in distal ulcerative colitis.The patients are treated with rosiglitazone enema, once a day, for fourteen days. Disease activity was assessed before and after treatment by endoscopical and clinical activity score.

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Distal ulcerative colitis (Mayo Clinical Score > 7)
• Age > 18 years
• Written consent

Exclusion criteria

• Age < 18 years
• Severe ulcerative colitis
• Systemic treatment with steroids or azathioprin within the last 3 month
• Known liver or kidney disease
• Severe heart failure
• Pregnancy or breast feeding

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind